Design, Synthesis and Molecular Modeling Studies of Triazole Derivatives as Aromatase İnhibitors
Chemical Biology & Drug Design · 2026-05 · 107 (5)
DOI: 10.1111/cbdd.70322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 21.05.2026. Verfasst von Emine Rana Bağcı und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey. Hauptthemen laut MEDLINE: Triazoles, Aromatase Inhibitors, Drug Design, Antineoplastic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anadolu Üniversitesi.
Abstract (Originalsprache)
Based on the structural characteristics of non‐steroidal aromatase inhibitors used in the treatment of estrogen receptor‐positive (ER+) breast cancer, a novel series of 1,3,4‐triazole derivatives was designed and synthesized in this study. The cytotoxicity of the synthesized compounds was evaluated against the MCF‐7 human breast cancer cell line using the MTT assay. In contrast, the L929 mouse fibroblast cell line was employed as a normal cell model to assess selectivity. Among the tested derivatives, compounds 6e and 6g exhibited significant cytotoxic activity against MCF‐7 cells, with IC₅₀ values of 19.96 μM and 15.75 μM, respectively, demonstrating stronger activity than the reference drug cisplatin (21.42 μM). In contrast, compounds 6k and 6l showed lower cytotoxicity toward L929 cells and displayed favorable selectivity profiles. Based on their cytotoxic potency and selectivity indices, compounds 6g , 6e , 6l , and 6k were selected for further biological and in silico investigations. Aromatase inhibition assays revealed that these compounds inhibited the enzyme with IC₅₀ values of 8.59, 11.98, 11.41, and 7.69 μM, respectively. Molecular docking analysis demonstrated that the selected compounds exhibited binding interactions similar to letrozole within the aromatase active site. Based on combined cytotoxicity, enzyme inhibition, molecular docking, and ADME predictions, compound 6l emerged as the most promising candidate as a potential non‐steroidal aromatase inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.
- Institute of Graduate Education, Anadolu University, Eskisehir, Turkey.
- Faculty of Pharmacy, Department of Biochemistry, Sivas Cumhuriyet University, Sivas, Turkiye.
- Medicinal Plant, Drug and Scientific Research and Application Center (AUBIBAM), Eskişehir, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.
- The Graduate School of Health Sciences, Ankara University, Ankara, Turkey.
ORCID-Profile: Şennur Görgülü, İsmail Çelik, Ulviye Acar Çevik
Förderung
- Anadolu Üniversitesi
Zitieren
APA
Bağcı, E. R., Bostancı, H. E., Görgülü, Ş., Yıldırım, M., Çelik, İ., & Acar Çevik, U. (2026). Design, Synthesis and Molecular Modeling Studies of Triazole Derivatives as Aromatase İnhibitors. Chemical Biology & Drug Design, 107(5). https://doi.org/10.1111/cbdd.70322
Vancouver
Bağcı ER, Bostancı HE, Görgülü Ş, Yıldırım M, Çelik İ, Acar Çevik U. Design, Synthesis and Molecular Modeling Studies of Triazole Derivatives as Aromatase İnhibitors. Chemical Biology & Drug Design. 2026;107(5). doi:10.1111/cbdd.70322
BibTeX
@article{Bac2026,
author = {Bağcı, Emine Rana and Bostancı, Hayrani Eren and Görgülü, Şennur and Yıldırım, Merve and Çelik, İsmail and Acar Çevik, Ulviye},
title = {Design, Synthesis and Molecular Modeling Studies of Triazole Derivatives as Aromatase İnhibitors},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {5},
doi = {10.1111/cbdd.70322}
}
EUVIMED